drugset / Trial / NCT07153068
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study was to evaluate the safety and efficacy of supCD7 CART cells in the treatment of patients with relapsed/refractory CD7-positive hematologic malignancies. In this single-arm, open-label, single-center, Phase Ⅰ+Ⅱ clinical trial, two cohorts were set up: (1) relapsed and refractory AML cohort; and (2) relapsed and refractory T-ALL/LBL cohort. Each cohort was planned to enroll 4-12 patients. SupCD7 CART cells will be administered intravenously to explore the MTD of each cohort using a 3+3 dose escalation and rapid titration design.
Timeline
- Start
- 2025-06-28
- Primary completion
- 2028-06-28
- Completion
- 2030-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | supCD7 CART cells | Cell therapy | 0.5 cells/kg | Intravenous |
| Subject | supCD7 CART cells | Cell therapy | 1 cells/kg | Intravenous |
| Subject | supCD7 CART cells | Cell therapy | 3 cells/kg | Intravenous |